Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by CancerSlayeron Feb 02, 2023 8:29pm
325 Views
Post# 35263757

RE:Quick poll

RE:Quick poll

 

I think an expedited approval in whatever form is almost a foregone conclusion based on the optimized data trends...I'm not too concerned about the "if" & I never like to predict the "when" in this business, but I'd certainly consider an approval to be a "near-term" event when viewed in the context of the number of years most here have been invested.  

The better question imo is what is the best path moving forward to expedite adoption of our ACT?  As I've stated in the past, I'm hoping an influencer in the field (I.e. physician(s) &/or influential treatment center/academic institution) can carry the torch for TLT.  An important pre-commercialization step for a promising tech is making those important connections with not only Pharma, but with physician leaders & major centers that make up an integral part of establishing SOC/new treatment guidelines to be adopted.  We all want a quick ROI, but we also need to stay patient & keep in mind there are a lot of moving parts.  The more these parts work together/in parallel, the earlier the commercial success...this is when true value is created.  I'm staying patient until that fruition.  Good luck...

<< Previous
Bullboard Posts
Next >>